## Review of insulin and insulin-like growth factor express the central nervous system: Relevance to Alzheimer's d

Journal of Alzheimer's Disease 7, 45-61 DOI: 10.3233/jad-2005-7106

**Citation Report** 

#	Article	IF	CITATIONS
1	Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. International Journal of Molecular Medicine, 1998, 22, 529.	1.8	63
2	Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. Journal of Alzheimer's Disease, 2005, 8, 247-268.	1.2	631
3	Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033-1036.	1.6	35
4	Increased risk of Alzheimer's disease in TypeÂll diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochemical Society Transactions, 2005, 33, 1041-1044.	1.6	211
5	Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033.	1.6	63
6	Can herbs provide a new generation of drugs for treating Alzheimer's disease?. Brain Research Reviews, 2005, 50, 361-376.	9.1	116
7	Lipidâ~'Protein Interactions of Growth Factor Receptor-Bound Protein 14 in Insulin Receptor Signalingâ€. Biochemistry, 2005, 44, 15461-15471.	1.2	15
8	Proteolytic mechanisms in amyloid-β metabolism: therapeutic implications for Alzheimer's disease. Trends in Molecular Medicine, 2005, 11, 464-472.	3.5	116
9	Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: A single-center, multiple-dose, open-label study. Clinical Therapeutics, 2005, 27, 1596-1606.	1.1	25
10	Increased risk of Alzheimer's disease in TypeÂll diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochemical Society Transactions, 2005, 33, 1041.	1.6	190
11	Mitochondrial Oxidative Damage in Aging and Alzheimer's Disease: Implications for Mitochondrially Targeted Antioxidant Therapeutics. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-13.	3.0	124
12	Early developmental expression of two insulins in zebrafish (Danio rerio). Physiological Genomics, 2006, 27, 79-85.	1.0	61
13	Treatment of dementia: anything new?. Current Opinion in Psychiatry, 2006, 19, 575-580.	3.1	6
14	Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 167-181.	1.2	277
15	Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 13-33.	1.2	415
16	Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 10, 89-109.	1.2	291
17	Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. Journal of Neurochemistry, 2006, 96, 1005-1015.	2.1	196
18	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Molecular Psychiatry, 2006, 11, 721-736.	4.1	334

#	Article	IF	CITATIONS
19	Canine cognitive deficit correlates with diffuse plaque maturation and S100β (â^') astrocytosis but not with insulin cerebrospinal fluid level. Acta Neuropathologica, 2006, 111, 519-528.	3.9	50
20	Resveratrol—A boon for treating Alzheimer's disease?. Brain Research Reviews, 2006, 52, 316-326.	9.1	320
21	Inhibition of CSK3 Dependent Tau Phosphorylation by Metals. Current Alzheimer Research, 2006, 3, 123-127.	0.7	26
22	Hyperinsulinemia and Cognitive Decline in a Middle-Aged Cohort. Diabetes Care, 2006, 29, 2688-2693.	4.3	153
24	G-protein-coupled Receptor Rhodopsin Regulates the Phosphorylation of Retinal Insulin Receptor. Journal of Biological Chemistry, 2007, 282, 9865-9873.	1.6	39
25	A New Glucocorticoid Hypothesis of Brain Aging: Implications for Alzheimers Disease. Current Alzheimer Research, 2007, 4, 205-212.	0.7	137
27	Type 2 Diabetes and Alzheimer's Disease: From Common Pathologies to Potential New Therapeutics. Journal of Diabetes Science and Technology, 2007, 1, 590-594.	1.3	2
29	Increased Circulating Insulin-like Growth Factor-1 in Late-onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 12, 285-290.	1.2	95
30	Laser microdissection and microarray analysis of the hippocampus of Ras-GRF1 knockout mice reveals gene expression changes affecting signal transduction pathways related to memory and learning. Neuroscience, 2007, 146, 272-285.	1.1	45
32	Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway. Journal of Biological Chemistry, 2007, 282, 33305-33312.	1.6	288
33	Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. , 2007, , 217-233.		182
34	Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function—role of glucose metabolism and insulin signalling. Archives of Physiology and Biochemistry, 2007, 113, 131-141.	1.0	46
35	Dynamic O-GlcNAcylation of Nucleocytoplasmic Proteins. , 2007, , 193-208.		0
36	Insulin and Insulinâ€Like Growth Factor Resistance With Neurodegeneration in an Adult Chronic Ethanol Exposure Model. Alcoholism: Clinical and Experimental Research, 2007, 31, 1558-1573.	1.4	88
37	Mitochondrial respiratory chain is involved in insulin-stimulated hydrogen peroxide production and plays an integral role in insulin receptor autophosphorylation in neurons. BMC Neuroscience, 2007, 8, 84.	0.8	60
38	Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Research Reviews, 2007, 56, 384-402.	9.1	322
39	Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology, 2007, 32, 1041-1051.	1.3	102
40	Chaperone-like activity of immunophilin FKBP12 from bovine brain, a cytoplasmic receptor of immunosuppressor FK506. Neurochemical Journal, 2007, 1, 196-203.	0.2	3

#	Article	IF	CITATIONS
41	Systemic and Brain Metabolic Dysfunction as a New Paradigm for Approaching Alzheimer's Dementia. Neurochemical Research, 2007, 32, 555-567.	1.6	42
42	Indices of Metabolic Dysfunction and Oxidative Stress. Neurochemical Research, 2007, 32, 717-722.	1.6	23
43	Beta-Amyloid Toxicity in Embryonic Rat Astrocytes. Neurochemical Research, 2007, 32, 1476-1482.	1.6	19
44	Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Human Genetics, 2007, 122, 1-21.	1.8	63
45	Chronic ethanol exposure causes mitochondrial dysfunction and oxidative stress in immature central nervous system neurons. Acta Neuropathologica, 2007, 113, 659-673.	3.9	96
47	Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia, 2008, 51, 657-667.	2.9	111
48	Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25–35)-induced amnesia. BMC Pharmacology, 2008, 8, 1.	0.4	30
49	Defective insulin signaling pathway and increased glycogen synthase kinaseâ€3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. Journal of Neuroscience Research, 2008, 86, 3265-3274.	1.3	259
50	Insulin and Insulin‣ike Growth Factor Resistance in Alcoholic Neurodegeneration. Alcoholism: Clinical and Experimental Research, 2008, 32, 1630-1644.	1.4	51
51	Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. Journal of Neurochemistry, 2008, 106, 1977-1990.	2.1	136
52	Insulin resistance in experimental alcoholâ€induced liver disease. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e477-86.	1.4	67
53	Separating cause from effect: how does insulin/IGF signalling control lifespan in worms, flies and mice?. Journal of Internal Medicine, 2008, 263, 179-191.	2.7	138
54	Regional and cellular distribution patterns of insulin-degrading enzyme in the adult human brain and pituitary. Journal of Chemical Neuroanatomy, 2008, 35, 216-224.	1.0	22
55	Translational gene mapping of cognitive decline. Neurobiology of Aging, 2008, 29, 524-541.	1.5	28
56	Synergistic premalignant effects of chronic ethanol exposure and insulin receptor substrateâ€1 overexpression in liver. Hepatology Research, 2008, 38, 940-953.	1.8	5
57	Physical Activity Participation May Offset Some of the Negative Impact of Diabetes on Cognitive Function. Journal of the American Medical Directors Association, 2008, 9, 434-438.	1.2	57
58	The Role of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in Alzheimer's Disease. CNS Drugs, 2008, 22, 1-14.	2.7	155
59	Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed. Journal of Diabetes Science and Technology, 2008, 2, 1101-1113.	1.3	853

#	Article	IF	CITATIONS
60	Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment. Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	2
61	Limited Alzheimer-Type Neurodegeneration in Experimental Obesity and Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2008, 15, 29-44.	1.2	130
62	Metabolic Syndrome and Alzheimer's Disease: <i>A Link to a Vascular Hypothesis?</i> . CNS Spectrums, 2008, 13, 606-613.	0.7	88
63	An Integrated and Unifying Hypothesis for the Metabolic Basis of Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 13, 241-253.	1.2	85
64	Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy. Clinical Medicine Pathology, 2008, 1, CPath.S667.	0.0	11
65	Epidemiological Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis. Journal of Alzheimer's Disease, 2009, 17, 519-529.	1.2	83
66	Brain Insulin-Like Growth Factor and Neurotrophin Resistance in Parkinson's Disease and Dementia with Lewy Bodies: Potential Role of Manganese Neurotoxicity. Journal of Alzheimer's Disease, 2009, 16, 585-599.	1.2	74
67	Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. Pharmaceuticals, 2009, 2, 250-286.	1.7	9
68	The Liver-Brain Axis of Alcohol-Mediated Neurodegeneration: Role of Toxic Lipids. International Journal of Environmental Research and Public Health, 2009, 6, 2055-2075.	1.2	114
69	Mechanisms of Nitrosamine-Mediated Neurodegeneration: Potential Relevance to Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 817-825.	1.2	81
70	Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial. Journal of Medical Genetics, 2009, 46, 217-222.	1.5	44
71	The Model Caenorhabditis elegans in Diabetes Mellitus and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 897-908.	1.2	28
72	The human insulin receptor mRNA contains a functional internal ribosome entry segment. Nucleic Acids Research, 2009, 37, 5881-5893.	6.5	41
73	Insulin Signaling in Sporadic Alzheimer's Disease. Science Signaling, 2009, 2, pe36.	1.6	34
74	New Perspectives for the Diagnosis of Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2009, 4, 160-181.	0.9	15
75	Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. Current Psychiatry Reviews, 2009, 5, 73-92.	0.9	112
77	GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. Human Molecular Genetics, 2009, 18, 4629-4639.	1.4	61
78	Increased Tau Phosphorylation and Cleavage in Mouse Models of Type 1 and Type 2 Diabetes. Endocrinology, 2009, 150, 5294-5301.	1.4	220

#	Article	IF	CITATIONS
79	The Role of IGF-1 Receptor and Insulin Receptor Signaling for the Pathogenesis of Alzheimers Disease: From Model Organisms to Human Disease. Current Alzheimer Research, 2009, 6, 213-223.	0.7	131
80	Insulin/IGF-like signalling, the central nervous system and aging. Biochemical Journal, 2009, 418, 1-12.	1.7	206
81	Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. Journal of Psychiatric Research, 2009, 43, 1095-1105.	1.5	23
82	The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Research Reviews, 2009, 59, 293-315.	9.1	463
83	Growth factors and glucose homeostasis in diabetic rats: effects of exercise training. Cell Biochemistry and Function, 2009, 27, 199-204.	1.4	15
84	Effects of exercise training on hippocampus concentrations of insulin and IGFâ€1 in diabetic rats. Hippocampus, 2009, 19, 981-987.	0.9	27
85	Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age, 2009, 31, 39-49.	3.0	63
86	A universal pathway for amyloid nucleus and precursor formation for insulin. Proteins: Structure, Function and Bioinformatics, 2009, 74, 556-565.	1.5	68
87	Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Molecular Neurodegeneration, 2009, 4, 54.	4.4	72
88	Brain glucose transporters, <i>O</i> â€GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. Journal of Neurochemistry, 2009, 111, 242-249.	2.1	167
89	Ethanol inhibition of aspartyl-asparaginyl-β-hydroxylase in fetal alcohol spectrum disorder: Potential link to the impairments in central nervous system neuronal migration. Alcohol, 2009, 43, 225-240.	0.8	49
90	Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ. Journal of Biological Chemistry, 2009, 284, 18742-18753.	1.6	130
91	Insulin is a Two-Edged Knife on the Brain. Journal of Alzheimer's Disease, 2009, 18, 483-507.	1.2	124
92	Insulin resistence and health-related quality of life in postmenopausal women. Fertility and Sterility, 2009, 91, 1370-1373.	0.5	14
93	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 482-496.	1.8	291
94	(Pre)diabetes, brain aging, and cognition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 432-443.	1.8	296
95	Mechanisms involved in cholesterol-induced neuronal insulin resistance. Neuropharmacology, 2009, 57, 268-276.	2.0	29
97	Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease. Neuroscience Letters, 2009, 460, 180-184.	1.0	18

#	Article	IF	CITATIONS
98	Common Pathological Processes and Transcriptional Pathways in Alzheimer's Disease and Type 2 Diabetes. Journal of Alzheimer's Disease, 2009, 16, 787-808.	1.2	49
99	Hippocampal Alterations in Rats Submitted to Streptozotocin-Induced Dementia Model are Prevented by Aminoguanidine. Journal of Alzheimer's Disease, 2009, 17, 193-202.	1.2	53
100	An Integrative View of the Role of Oxidative Stress, Mitochondria and Insulin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 741-761.	1.2	172
101	Rethinking Alzheimer's Disease Therapy: Are Mitochondria the Key?. Journal of Alzheimer's Disease, 2010, 20, S579-S590.	1.2	47
102	Ceramide-Mediated Insulin Resistance and Impairment of Cognitive-Motor Functions. Journal of Alzheimer's Disease, 2010, 21, 967-984.	1.2	86
103	Chrelin Modulates Insulin Sensitivity and Tau Phosphorylation in High Glucose-Induced Hippocampal Neurons. Biological and Pharmaceutical Bulletin, 2010, 33, 1165-1169.	0.6	42
104	Differences in the body composition and biochemistry in women grouped as normal-weight, overweight and obese according to body mass index and their relation with cardiometabolic risk. Open Medicine (Poland), 2010, 5, 724-732.	0.6	2
106	Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases. Molecular Neurobiology, 2010, 41, 375-383.	1.9	283
107	Rhodopsin-regulated Insulin Receptor Signaling Pathway in Rod Photoreceptor Neurons. Molecular Neurobiology, 2010, 42, 39-47.	1.9	35
108	Insulin and IGF-1 receptors, nitrotyrosin and cerebral neuronal deficits in two young patients with diabetic ketoacidosis and fatal brain edema. Brain Research, 2010, 1343, 168-177.	1.1	20
109	Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. BMC Endocrine Disorders, 2010, 10, 4.	0.9	58
110	Insulin inhibits Aβ fibrillogenesis through a decrease of the GM1 gangliosideâ€rich microdomain in n neuronal membranes. Journal of Neurochemistry, 2010, 113, 628-636.	2.1	10
111	Late onset Alzheimer's disease in older people. Clinical Interventions in Aging, 2010, 5, 307.	1.3	89
112	The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology. Reviews in the Neurosciences, 2010, 21, 83-93.	1.4	72
113	Rat Strain Differences in Susceptibility to Alcohol-Induced Chronic Liver Injury and Hepatic Insulin Resistance. Gastroenterology Research and Practice, 2010, 2010, 1-16.	0.7	43
115	How does diabetes accelerate Alzheimer disease pathology?. Nature Reviews Neurology, 2010, 6, 551-559.	4.9	362
116	The Brain-insulin Connection, Metabolic Diseases and Related Pathologies. Research and Perspectives in Alzheimer's Disease, 2010, , 21-42.	0.1	6
117	Role of aspartyl-(asparaginyl)-β-hydroxylase mediated notch signaling in cerebellar development and function. Behavioral and Brain Functions, 2010, 6, 68.	1.4	23

#	Article	IF	CITATIONS
118	Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease. Mitochondrion, 2010, 10, 32-37.	1.6	44
119	Sex difference in alcoholism: Who is at a greater risk for development of alcoholic complication?. Life Sciences, 2010, 87, 133-138.	2.0	140
120	Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 67-79.	1.1	95
121	Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiology of Aging, 2010, 31, 224-243.	1.5	659
122	Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Research Reviews, 2010, 9, 399-417.	5.0	292
123	Insulin-Like Growth Factor 2 Receptor Is an IFNÎ <sup>3</sup> -Inducible Microglial Protein that Facilitates Intracellular HIV Replication. American Journal of Pathology, 2010, 177, 2446-2458.	1.9	27
124	Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?. Journal of Alzheimer's Disease, 2010, 21, 57-63.	1.2	69
125	Diabetes, Insulin and Alzheimer's Disease. Research and Perspectives in Alzheimer's Disease, 2010, , .	0.1	7
126	Potential Predictors of Hippocampal Atrophy in Alzheimer's Disease. Drugs and Aging, 2011, 28, 1-11.	1.3	75
127	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , .		7
127 128	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , . Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.	5.0	7 195
127 128 129	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , .         Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.         IGF1R mutations as cause of SGA. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 191-206.	5.0	7 195 85
127 128 129 130	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , .         Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.         IGF1R mutations as cause of SGA. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 191-206.         The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology, 2011, 150, 123-129.	5.0 2.2 0.8	7 195 85 34
127 128 129 130	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , .         Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.         IGF1R mutations as cause of SGA. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 191-206.         The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology, 2011, 150, 123-129.         Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer〙s-like changes. Neuropharmacology, 2011, 60, 910-920.	5.0 2.2 0.8 2.0	7 195 85 34 241
127 128 129 130 131	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , .         Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.         IGF1R mutations as cause of SGA. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 191-206.         The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology, 2011, 150, 123-129.         Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimerãe™s-like changes. Neuropharmacology, 2011, 60, 910-920.         The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SYSY cells and rat hippocampus neuronal synapses. Neuroscience, 2011, 173, 169-178.	5.0 2.2 0.8 2.0 1.1	<ul> <li>7</li> <li>195</li> <li>85</li> <li>34</li> <li>241</li> <li>19</li> </ul>
127 128 129 130 131 132	Brain Imaging in Behavioral Medicine and Clinical Neuroscience., 2011, , .         Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.         IGF1R mutations as cause of SGA. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 191-206.         The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology, 2011, 150, 123-129.         Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology, 2011, 60, 910-920.         The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SY5Y cells and rat hippocampus neuronal synapses. Neuroscience, 2011, 173, 169-178.         The AÎ2 oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiology of Learning and Memory, 2011, 96, 529-543.	5.0 2.2 0.8 2.0 1.1 1.0	7 195 85 34 241 19 386
<ol> <li>127</li> <li>128</li> <li>129</li> <li>130</li> <li>131</li> <li>132</li> <li>133</li> <li>134</li> </ol>	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. , 2011, , .         Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.         IGF1R mutations as cause of SGA. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 191-206.         The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology, 2011, 150, 123-129.         Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology, 2011, 60, 910-920.         The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SYSY cells and rat hippocampus neuronal synapses. Neuroscience, 2011, 173, 169-178.         The Aî² oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiology of Learning and Memory, 2011, 96, 529-543.         Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiology of Learning and Memory, 2011, 96, 432-442.	5.0 2.2 0.8 2.0 1.1 1.0	7         195         85         34         241         19         386         163

#	ARTICLE	IF	CITATIONS
136 137	Acetaldehyde-Mediated Neurotoxicity: Relevance to Fetal Alcohol Spectrum Disorders. Oxidative Medicine and Cellular Longevity. 2011, 2011, 1-13.	1.9	1 28
138	Alzheimer's Disease and Type 2 Diabetes: Different Pathologies and Same Features. , 0, , .		3
139	ERK5: A Novel IKKα-Kinase in Rat Hippocampal Neurons. Canadian Journal of Neurological Sciences, 2011, 38, 639-648.	0.3	6
140	Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. Journal of Neural Transmission, 2011, 118, 765-772.	1.4	117
142	si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Molecular Brain, 2011, 4, 13.	1.3	47
143	Novel GLPâ€1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. Journal of Neuroscience Research, 2011, 89, 481-489.	1.3	178
145	Insulinâ€Directed Synthesis of Fluorescent Gold Nanoclusters: Preservation of Insulin Bioactivity and Versatility in Cell Imaging. Angewandte Chemie - International Edition, 2011, 50, 7056-7060.	7.2	391
146	Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease. Current Neuropharmacology, 2011, 9, 693-705.	1.4	26
147	Alzheimer's Disease: Emerging Trends in Small Molecule Therapies. Current Medicinal Chemistry, 2011, 18, 4299-4320.	1.2	53
148	Associations between Genetic Polymorphisms of Insulin-like Growth Factor Axis Genes and Risk for Age-Related Macular Degeneration. , 2011, 52, 9099.		21
149	Neural Networks, Cognition, and Diabetes: What Is the Connection?. Diabetes, 2012, 61, 1653-1655.	0.3	10
150	Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. CNS and Neurological Disorders - Drug Targets, 2012, 11, 482-489.	0.8	39
151	Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease. Current Alzheimer Research, 2012, 9, 35-66.	0.7	373
152	Triangulated Mal-Signaling in Alzheimer's Disease: Roles of Neurotoxic Ceramides, ER Stress, and Insulin Resistance Reviewed. Journal of Alzheimer's Disease, 2012, 30, S231-S249.	1.2	78
153	Insulin-like growth factor 1 (IGF1) polymorphism is associated with Alzheimer's disease in Han Chinese. Neuroscience Letters, 2012, 531, 20-23.	1.0	22
154	Different Approaches, One Target: Understanding Cellular Mechanisms of Parkinson's and Alzheimer's Diseases. Revista Brasileira De Psiquiatria, 2012, 34, 194-218.	0.9	9
155	Physical Exercise Exacerbates Memory Deficits Induced by Intracerebroventricular STZ but Improves Insulin Regulation of H2O2 Production in Mice Synaptosomes. Journal of Alzheimer's Disease, 2012, 30, 889-898.	1.2	18

#	Article	IF	Citations
156	Upregulation of the E3 ligase NEDD4-1 by Oxidative Stress Degrades IGF-1 Receptor Protein in Neurodegeneration. Journal of Neuroscience, 2012, 32, 10971-10981.	1.7	77
157	Locally released small (nonâ€protein) ninhydrinâ€reacting molecules underlie developmental differences of cultured medullary versus spinal dorsal horn neurons. Journal of Neurochemistry, 2012, 122, 605-618.	2.1	3
158	Down-regulation of IGF-1/IGF-1R in hippocampus of rats with vascular dementia. Neuroscience Letters, 2012, 513, 20-24.	1.0	42
159	Insulin in Central Nervous System: More than Just a Peripheral Hormone. Journal of Aging Research, 2012, 2012, 1-21.	0.4	227
160	Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults. Archives of Neurology, 2012, 69, 1420.	4.9	106
161	Brain insulin resistance accelerates Aβ fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. Journal of Neurochemistry, 2012, 121, 619-628.	2.1	43
162	Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer's Disease. Drugs, 2012, 72, 49-66.	4.9	202
163	Modulatory effects of vitamin E, acetyl-l-carnitine and α-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model. Experimental and Toxicologic Pathology, 2012, 64, 549-556.	2.1	30
164	Neuroprotective effect of preadministration with Ganoderma lucidum spore on rat hippocampus. Experimental and Toxicologic Pathology, 2012, 64, 673-680.	2.1	56
165	Identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression. NeuroImage, 2012, 63, 1681-1694.	2.1	74
166	Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiology and Behavior, 2012, 107, 401-413.	1.0	63
167	Early intranasal insulin therapy halts progression of neurodegeneration: progress in Alzheimer's disease therapeutics. Aging Health, 2012, 8, 61-64.	0.3	28
168	GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Reviews in the Neurosciences, 2012, 23, 1-11.	1.4	135
169	Tau Phosphorylation and μ-Calpain Activation Mediate the Dexamethasone-Induced Inhibition on the Insulin-Stimulated Akt Phosphorylation. PLoS ONE, 2012, 7, e35783.	1.1	5
170	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	1.1	89
171	In Vivo Cross-sectional Characterization of Cerebral Alterations Induced by Intracerebroventricular Administration of Streptozotocin. PLoS ONE, 2012, 7, e46196.	1.1	83
172	Impaired Insulin/IGF Signaling in Experimental Alcohol-Related Myopathy. Nutrients, 2012, 4, 1058-1075.	1.7	29
173	Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Frontiers in Bioscience - Elite, 2012, E4, 1582.	0.9	39

#	Article	IF	CITATIONS
174	Experimental Alcohol-Related Peripheral Neuropathy: Role of Insulin/IGF Resistance. Nutrients, 2012, 4, 1042-1057.	1.7	19
175	Cytoprotective effects of hesperetin and hesperidin against amyloid βâ€induced impairment of glucose transport through downregulation of neuronal autophagy. Molecular Nutrition and Food Research, 2012, 56, 601-609.	1.5	81
176	Alzheimer's Disease and Diabetes: An Integrative View of the Role of Mitochondria, Oxidative Stress, and Insulin. Journal of Alzheimer's Disease, 2012, 30, S199-S215.	1.2	67
177	Resveratrol Attenuates Obesity-Associated Peripheral and Central Inflammation and Improves Memory Deficit in Mice Fed a High-Fat Diet. Diabetes, 2012, 61, 1444-1454.	0.3	295
178	Functional Roles of Gangliosides in Neurodevelopment: An Overview of Recent Advances. Neurochemical Research, 2012, 37, 1230-1244.	1.6	168
179	American ginseng improves neurocognitive function in senescenceâ€accelerated mice: Possible role of the upregulated insulin and choline acetyltransferase gene expression. Geriatrics and Gerontology International, 2012, 12, 123-130.	0.7	7
180	Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation. Brain Research, 2012, 1441, 64-78.	1.1	164
181	Metabolic syndrome as a risk factor for neurological disorders. Cellular and Molecular Life Sciences, 2012, 69, 741-762.	2.4	164
182	BDNF-, IGF-1- and GDNF-Secreting Human Neural Progenitor Cells Rescue Amyloid β-Induced Toxicity in Cultured Rat Septal Neurons. Neurochemical Research, 2012, 37, 143-152.	1.6	68
183	Recent rodent models for Alzheimer's disease: clinical implications and basic research. Journal of Neural Transmission, 2012, 119, 173-195.	1.4	97
184	Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF. Physiology and Behavior, 2013, 109, 69-74.	1.0	57
185	Alzheimer's Dementia and Lifestyle: Towards a Primary Prevention. , 2013, , 193-214.		2
187	The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease. NeuroMolecular Medicine, 2013, 15, 102-114.	1.8	134
188	Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. Journal of Pharmacy and Pharmacology, 2013, 65, 1773-1784.	1.2	123
189	Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats. Neuroscience Letters, 2013, 543, 115-120.	1.0	59
190	What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. Journal of Neural Transmission, 2013, 120, 233-252.	1.4	220
191	Stress contributes to the development of central insulin resistance during aging: Implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2332-2339.	1.8	35
192	Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 527-541.	1.8	113

#	Article	IF	CITATIONS
194	Food for thought: The role of appetitive peptides in age-related cognitive decline. Ageing Research Reviews, 2013, 12, 764-776.	5.0	55
196	In vivo Metabolic Imaging of Insulin with Multiphoton Fluorescence of Human Insulin–Au Nanodots. Small, 2013, 9, 2103-2110.	5.2	17
197	Age-Related Changes in the Phospholipase D-Dependent Signal Pathway of Insulin in the Rat Neocortex. Neurophysiology, 2013, 45, 120-127.	0.2	4
198	Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle–Aged Adults. Diabetes Care, 2013, 36, 443-449.	4.3	173
199	Alzheimer's disease and type 2 diabetes: Two diseases, one common link?. World Journal of Biological Psychiatry, 2013, 14, 233-240.	1.3	16
200	mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer's disease. Molecular Medicine Reports, 2013, 7, 623-627.	1.1	42
201	Diabetes Cognitive Impairments and the Effect of Traditional Chinese Herbs. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	13
202	FK506 attenuates intracerebroventricular streptozotocin-induced neurotoxicity in rats. Behavioural Pharmacology, 2013, 24, 580-589.	0.8	20
203	Cinnamon Counteracts the Negative Effects of a High Fat/High Fructose Diet on Behavior, Brain Insulin Signaling and Alzheimer-Associated Changes. PLoS ONE, 2013, 8, e83243.	1.1	53
204	New animal models of Alzheimer's disease that display insulin desensitization in the brain. Reviews in the Neurosciences, 2013, 24, 607-15.	1.4	27
206	Insulin/IGF Signaling-Related Gene Expression in the Brain of a Sporadic Alzheimer's Disease Monkey Model Induced by Intracerebroventricular Injection of Streptozotocin. Journal of Alzheimer's Disease, 2013, 38, 251-267.	1.2	42
207	Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opinion on Drug Delivery, 2013, 10, 1699-1709.	2.4	68
208	Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI. PLoS ONE, 2013, 8, e55531.	1.1	41
211	A Pilot Study to Examine the Correlation between Cognition and Blood Biomarkers in a Singapore Chinese Male Cohort with Type 2 Diabetes Mellitus. PLoS ONE, 2014, 9, e96874.	1.1	8
212	Treatment of Insulin Resistance in the Neurodegeneration. Recent Patents on CNS Drug Discovery, 2014, 9, 54-63.	0.9	4
213	Treadmill exercise alleviates impairment of spatial learning ability through enhancing cell proliferation in the streptozotocin-induced Alzheimer's disease rats. Journal of Exercise Rehabilitation, 2014, 10, 81-88.	0.4	34
214	Metabolic regulation by protein tyrosine phosphatases. Journal of Biomedical Research, 2014, 28, 157-68.	0.7	11
215	Metabolic tinkering by the gut microbiome. Gut Microbes, 2014, 5, 369-380.	4.3	105

# 216	ARTICLE Experimental Induction of Type 2 Diabetes in Aging-Accelerated Mice Triggered Alzheimer-Like Pathology and Memory Deficits. Journal of Alzheimer's Disease, 2014, 39, 145-162.	IF 1.2	CITATIONS 83
217	Fetal alcohol spectrum disorders and cognitive functions of young children. Reviews in the Neurosciences, 2014, 25, 631-9.	1.4	23
218	Evidence for the Control of Aggrecanases by Insulin and Glucose in Alzheimer's Disease. Journal of Microbiology and Biotechnology, 2014, 24, 323-332.	0.9	5
219	Insulin resistance, neuroinflammation, and Alzheimer's disease. Reviews in the Neurosciences, 2014, 25, 509-25.	1.4	51
220	Perinatal exposure to diâ€{2â€ethylhexyl)â€phthalate leads to cognitive dysfunction and phosphoâ€ŧau level increase in aged rats. Environmental Toxicology, 2014, 29, 596-603.	2.1	29
221	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin. Neuropharmacology, 2014, 77, 68-80.	2.0	67
222	Role of Dietary and Endogenous Antioxidants in Diabetes. Critical Reviews in Food Science and Nutrition, 2014, 54, 1599-1616.	5.4	44
223	Gender Differences and Lateralization in the Distribution Pattern of Insulin-Like Growth Factor-1 Receptor in Developing Rat Hippocampus: An Immunohistochemical Study. Cellular and Molecular Neurobiology, 2014, 34, 215-226.	1.7	23
224	Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease. Behavioural Brain Research, 2014, 267, 55-65.	1.2	45
225	Spatial memory in sedentary and trained diabetic rats: Molecular mechanisms. Hippocampus, 2014, 24, 703-711.	0.9	28
226	Body growth and brain development in premature babies: an MRI study. Pediatric Radiology, 2014, 44, 297-304.	1.1	14
227	Brain metabolic dysfunction at the core of Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 548-559.	2.0	374
228	Task-Induced Brain Activity Patterns in Type 2 Diabetes: A Potential Biomarker for Cognitive Decline. Diabetes, 2014, 63, 3112-3119.	0.3	46
229	Adipokines and dementia. Postepy Psychiatrii I Neurologii, 2014, 23, 185-189.	0.2	0
230	Effects of analog P165 of amyloid precursor protein 5-mer peptide on learning, memory and brain insulin receptors in the rat model of cognitive decline. Neurological Sciences, 2014, 35, 1821-1826.	0.9	12
231	Relationships Between Diabetes and Cognitive Impairment. Endocrinology and Metabolism Clinics of North America, 2014, 43, 245-267.	1.2	63
232	Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. Journal of Neuroimmunology, 2014, 273, 8-21.	1.1	150
233	Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1693-1706.	1.8	286

#	Article	IF	CITATIONS
234	Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review. European Neuropsychopharmacology, 2014, 24, 1954-1960.	0.3	237
235	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. BMC Neurology, 2014, 14, 64.	0.8	46
236	Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. Journal of Alzheimer's Disease, 2015, 48, 891-917.	1.2	64
237	Neuropeptides II: function. , 0, , 286-350.		0
238	Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Scientific Reports, 2015, 4, 3754.	1.6	37
239	The aspartyl asparaginyl beta-hydroxylase in carcinomas. Frontiers in Bioscience - Landmark, 2015, 20, 902-909.	3.0	6
240	Mechanisms linking brain insulin resistance to Alzheimer's disease. Dementia E Neuropsychologia, 2015, 9, 96-102.	0.3	44
241	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Experimental and Molecular Medicine, 2015, 47, e149-e149.	3.2	225
243	Effect of Sancaijiangtang on plasma nitric oxide and endothelin-1 levels in patients with type 2 diabetes mellitus and vascular dementia: a single-blind randomized controlled trial. Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine, 2015, 35, 375-380.	0.4	15
244	Synergistic effects of GSK-3Î <sup>2</sup> and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 337-349.	1.4	37
245	Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed. Neurobiology of Aging, 2015, 36, 942-947.	1.5	39
246	Highly specific role of the insulin receptor in breast cancer progression. Endocrine-Related Cancer, 2015, 22, 145-157.	1.6	62
247	Associations between insulin action and integrity of brain microstructure differ with familial longevity and with age. Frontiers in Aging Neuroscience, 2015, 7, 92.	1.7	3
248	Serum IGF-BP2 strongly moderates age's effect on cognition: a MIMIC analysis. Neurobiology of Aging, 2015, 36, 2232-2240.	1.5	10
249	Inhibition of GSK3β by pharmacological modulation of sphingolipid metabolism occurs independently of ganglioside disturbance in a cellular model of Alzheimer's disease. Experimental Neurology, 2015, 271, 308-318.	2.0	4
250	Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides, 2015, 52, 1-18.	0.9	405
251	Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. Life Sciences, 2015, 136, 108-119.	2.0	46
252	Insulin, Aging, and the Brain: Mechanisms and Implications. Frontiers in Endocrinology, 2015, 6, 13.	1.5	91

$\sim$			<u> </u>	
( 11	ΓΔΤ	$1 \cap N$		ODT
$\sim$	IAI		IVEL	

#	Article	IF	CITATIONS
253	Mosaic pancreas and type 3 diabetes. International Journal of Diabetes in Developing Countries, 2015, 35, 387-387.	0.3	0
254	Caffeic acid improves memory impairment and brain glucose metabolism via ameliorating cerebral insulin and leptin signaling pathways in high-fat diet-induced hyperinsulinemic rats. Food Research International, 2015, 77, 24-33.	2.9	18
255	Growth factor treatment to overcome Alzheimer's dysfunctional signaling. Cellular Signalling, 2015, 27, 1025-1038.	1.7	28
256	role of IGF-1 in cortical plasticity and functional deficit induced by sensorimotor restriction. Behavioural Brain Research, 2015, 290, 117-123.	1.2	13
257	Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metabolic Brain Disease, 2015, 30, 895-901.	1.4	45
258	Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease. Journal of Neural Transmission, 2015, 122, 577-592.	1.4	101
259	Differential Contributions of Alcohol and the Nicotine-Derived Nitrosamine Ketone (NNK) to Insulin and Insulin-Like Growth Factor Resistance in the Adolescent Rat Brain. Alcohol and Alcoholism, 2015, 50, 670-679.	0.9	22
260	Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurological Sciences, 2015, 36, 1763-1769.	0.9	49
261	Restoration of Cerebral and Systemic Microvascular Architecture in <scp>APP</scp> / <scp>PS</scp> 1 Transgenic Mice Following Treatment with Liraglutide <sup>â,,¢</sup> . Microcirculation, 2015, 22, 133-145.	1.0	40
262	Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: An interdisciplinary perspective. Behavioural Brain Research, 2015, 276, 199-212.	1.2	71
263	Insulin resistance predicts brain amyloid deposition in late middleâ€ <b>e</b> ged adults. Alzheimer's and Dementia, 2015, 11, 504.	0.4	196
264	Ameliorative Effects of Nutraceuticals in Neurological Disorders. , 2015, , 245-260.		15
265	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. Journal of Alzheimer's Disease, 2016, 52, 1373-1383.	1.2	51
266	Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Dise ase Pathologies. , 2016, 6, .		29
267	Biological and biophysics aspects of metformin-induced effects: cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates. Aging, 2016, 8, 1718-1734.	1.4	48
268	Alcoholic Beverage and Insulin Resistance–Mediated Degenerative Diseases of Liver and Brain. , 2016, , 237-251.		0
269	T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 123-138.	1.2	38
270	Lipid microdomain modification sustains neuronal viability in models of Alzheimer's disease. Acta Neuropathologica Communications, 2016, 4, 103.	2.4	30

#	Article	IF	CITATIONS
271	Alzheimer's disease: Is this a brain specific diabetic condition?. Physiology and Behavior, 2016, 164, 259-267.	1.0	38
272	Exercise-induced neuroprotective effects on neurodegenerative diseases: the key role of trophic factors. Expert Review of Neurotherapeutics, 2016, 16, 723-734.	1.4	45
273	Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free Radical Biology and Medicine, 2016, 100, 108-122.	1.3	344
274	Enhanced-fluorescence of europium–copper nanoclusters for cell imaging. Journal of Materials Science, 2016, 51, 7229-7235.	1.7	8
275	Evaluating the Role of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease. Drugs and Aging, 2016, 33, 787-808.	1.3	10
276	Oral inflammation and infection, and chronic medical diseases: implications for the elderly. Periodontology 2000, 2016, 72, 153-175.	6.3	222
277	Fe–oxy adducts of heme–Aβ and heme–hIAPP complexes: intermediates in ROS generation. Metallomics, 2016, 8, 1266-1272.	1.0	12
278	Caenorhabditis elegans. , 2016, , 341-354.		3
279	ERK2 and Akt are negative regulators of insulin and Tumor Necrosis Factor-α stimulated VCAM-1 expression in rat aorta endothelial cells. Journal of Inflammation, 2016, 13, 6.	1.5	9
280	Withanolide A offers neuroprotection, ameliorates stress resistance and prolongs the life expectancy of Caenorhabditis elegans. Experimental Gerontology, 2016, 78, 47-56.	1.2	57
281	Brain Insulin Administration Triggers Distinct Cognitive and Neurotrophic Responses in Young and Aged Rats. Molecular Neurobiology, 2016, 53, 5807-5817.	1.9	38
282	Insulin-Like Growth Factor-1 Related to Disability Among Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 797-802.	1.7	21
283	The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 1905-1924.	1.9	73
284	Dynamics of diabetes and obesity: Epidemiological perspective. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1026-1036.	1.8	173
285	Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice. International Journal of Immunopathology and Pharmacology, 2017, 30, 25-43.	1.0	38
286	Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease. Molecular and Cellular Neurosciences, 2017, 82, 23-34.	1.0	11
287	Combined immunotherapy with "anti-insulin resistance―therapy as a novel therapeutic strategy against neurodegenerative diseases. Npj Parkinson's Disease, 2017, 3, 4.	2.5	19
288	The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway. CNS Drugs, 2017, 31, 535-549.	2.7	16

#	Article	IF	CITATIONS
289	Effect of Metformin on Adult Hippocampal Neurogenesis: Comparison with Donepezil and Links to Cognition. Journal of Molecular Neuroscience, 2017, 62, 88-98.	1.1	48
290	Associations of polymorphisms in the candidate genes for Alzheimer's disease BIN1, CLU, CR1 and PICALM with gestational diabetes and impaired glucose tolerance. Molecular Biology Reports, 2017, 44, 227-231.	1.0	12
291	Cerebellar Insulin/IGF-1 signaling in diabetic rats: Effects of exercise training. Neuroscience Letters, 2017, 639, 157-161.	1.0	5
292	DNA methylation and histone deacetylation regulating insulin sensitivity due to chronic cold exposure. Cryobiology, 2017, 74, 36-42.	0.3	7
293	Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease. Drugs, 2017, 77, 47-65.	4.9	211
294	The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. Diabetes Research and Clinical Practice, 2017, 123, 192-198.	1.1	125
295	A novel microglial subset plays a key role in myelinogenesis in developing brain. EMBO Journal, 2017, 36, 3292-3308.	3.5	375
296	Ferulic acid attenuates diabetes-induced cognitive impairment in rats via regulation of PTP1B and insulin signaling pathway. Physiology and Behavior, 2017, 182, 93-100.	1.0	61
297	Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology, 2017, 89, 1789-1794.	1.5	24
298	Gut microbiome alterations in Alzheimer's disease. Scientific Reports, 2017, 7, 13537.	1.6	1,256
299	Impact of morphine on the expression of insulin receptor and protein levels of insulin/IGFs in rat neural stem cells. Neuroscience Letters, 2017, 660, 147-154.	1.0	9
300	Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders. Advances in Neurobiology, 2017, 18, 113-142.	1.3	45
302	Autophagy-lysosome dysfunction is involved in Aβ deposition in STZ-induced diabetic rats. Behavioural Brain Research, 2017, 320, 484-493.	1.2	42
303	Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1078-1089.	1.8	393
304	Intranasal Insulin Administration Ameliorates Streptozotocin (ICV)-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Memory Impairment in Rats. Molecular Neurobiology, 2017, 54, 6507-6522.	1.9	67
305	Can Co-Activation of Nrf2 and Neurotrophic Signaling Pathway Slow Alzheimer's Disease?. International Journal of Molecular Sciences, 2017, 18, 1168.	1.8	41
306	Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. Frontiers in Endocrinology, 2017, 8, 173.	1.5	10
307	Experimental Models of Maternal Obesity and Neuroendocrine Programming of Metabolic Disorders in Offspring. Frontiers in Endocrinology, 2017, 8, 245.	1.5	27

#	Article	IF	CITATIONS
308	Brain Transcriptome Sequencing of a Natural Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2017, 9, 64.	1.7	14
309	DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy. Frontiers in Cellular Neuroscience, 2017, 11, 258.	1.8	1
310	The role of melatonin in the onset and progression of type 3 diabetes. Molecular Brain, 2017, 10, 35.	1.3	14
311	Chronic diabetic states worsen Alzheimer neuropathology and cognitive deficits accompanying disruption of calcium signaling in leptin-deficient APP/PS1 mice. Oncotarget, 2017, 8, 43617-43634.	0.8	27
313	GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes. Peptides, 2018, 100, 101-107.	1.2	46
314	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	1.9	24
315	The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at â€~Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments. Journal of Alzheimer's Disease, 2018, 62, 1381-1390.	1.2	48
316	The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review. Journal of Nutrition & Intermediary Metabolism, 2018, 14, 42-51.	1.7	26
317	Redox Signaling in Neurotransmission and Cognition During Aging. Antioxidants and Redox Signaling, 2018, 28, 1724-1745.	2.5	68
318	Association Between Insulin-Like Growth Factor-1 and Frailty Among Older Adults. Journal of Nutrition, Health and Aging, 2018, 22, 68-72.	1.5	25
319	Intranasal insulin treatment restores cognitive deficits and insulin signaling impairment induced by repeated methamphetamine exposure. Journal of Cellular Biochemistry, 2018, 119, 2345-2355.	1.2	35
320	Thyroid hormone improves insulin signaling and reduces the activation of neurodegenerative pathway in the hippocampus of diabetic adult male rats. Life Sciences, 2018, 192, 253-258.	2.0	16
321	Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus. Current Alzheimer Research, 2018, 15, 1277-1282.	0.7	25
322	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 124.	3.0	273
323	Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer's disease and normalized by treatment with anti-diabetic agents. PLoS ONE, 2018, 13, e0206547.	1.1	22
324	A Natural Dietary Supplement with a Combination of Nutrients Prevents Neurodegeneration Induced by a High Fat Diet in Mice. Nutrients, 2018, 10, 1130.	1.7	37
325	How carnivorous are we? The implication for protein consumption. Journal of Evolution and Health, 2018, 3, .	0.2	2
326	A review of brain insulin signaling in mood disorders: From biomarker to clinical target. Neuroscience and Biobehavioral Reviews, 2018, 92, 7-15.	2.9	26

#	Article	IF	CITATIONS
327	Streptozotocin-induced β-cell damage, high fat diet, and metformin administration regulate Hes3 expression in the adult mouse brain. Scientific Reports, 2018, 8, 11335.	1.6	5
328	Systems Pharmacological Approach to Investigate the Mechanism of <i> Acori Tatarinowii Rhizoma</i> for Alzheimer's Disease. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-20.	0.5	20
329	Design and Efficacy of Nanogels Formulations for Intranasal Administration. Molecules, 2018, 23, 1241.	1.7	46
330	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. Pharmaceuticals, 2018, 11, 11.	1.7	45
331	NO-Dependent Akt Inactivation by S-Nitrosylation as a Possible Mechanism of STZ-Induced Neuronal Insulin Resistance. Journal of Alzheimer's Disease, 2018, 65, 1427-1443.	1.2	9
332	Glucose, Insulin, and Human Brain Aging. , 2018, , 889-898.		2
333	Potential synaptic plasticityâ€based Shenzhiling oral liquid for a SAD Mouse Model. Brain and Behavior, 2019, 9, e01385.	1.0	7
334	Investigations of possible links between Alzheimer's disease and type 2 diabetes mellitus by positron emission tomography: a systematic review. Clinical and Translational Imaging, 2019, 7, 327-336.	1.1	2
335	A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. Behavioural Brain Research, 2019, 372, 112015.	1.2	12
336	The Novel Perspectives of Adipokines on Brain Health. International Journal of Molecular Sciences, 2019, 20, 5638.	1.8	59
337	Treatment strategies against diabetes: Success so far and challenges ahead. European Journal of Pharmacology, 2019, 862, 172625.	1.7	106
338	Neurocognitive impairment in type 2 diabetes mellitus. Hormones, 2019, 18, 523-534.	0.9	33
339	A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach. Current Diabetes Reviews, 2019, 15, 255-258.	0.6	5
340	The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes. Advances in Experimental Medicine and Biology, 2019, 1128, 45-83.	0.8	39
341	Altered Brain Expression of Insulin and Insulin-Like Growth Factors in Frontotemporal Lobar Degeneration: Another Degenerative Disease Linked to Dysregulation of Insulin Metabolic Pathways. ASN Neuro, 2019, 11, 175909141983951.	1.5	18
342	Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic. Frontiers in Molecular Neuroscience, 2019, 12, 132.	1.4	148
343	How stress mediators can cumulatively contribute to Alzheimer's disease An allostatic load approach. Dementia E Neuropsychologia, 2019, 13, 11-21.	0.3	21
344	Mechanical properties of RBCs under oxidative stress measured by optical tweezers. Optics Communications, 2019, 442, 56-59.	1.0	11

ARTICLE IF CITATIONS Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System 345 1.2 43 Dysregulation of Insulin-Linked Metabolic Pathways. Journal of Alzheimer's Disease, 2019, 68, 657-668. Hyperinsulinemia or Insulin Resistance: What Impacts the Progression of Alzheimer's Disease?. Journal 346 1.2 19 of Alzheimer's Disease, 2019, 72, S71-S79. Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity 347 1.3 22 Through Apoptosis Pathway and NO Modulation. Neurotoxicity Research, 2019, 35, 516-529. Impaired chemoreflex correlates with decreased c-Fos in respiratory brainstem centers of the 348 2.0 streptozotocin-induced Alzheimer's disease rat model. Experimental Neurology, 2019, 311, 285-292. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in 349 1.8 36 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E750-E764. MA-[d-Leu-4]-OB3, a Small Molecule Synthetic Peptide Leptin Mimetic, Mirrors the Cognitive Enhancing Action of Leptin in a Mouse Model of Type 1 Diabetes Mellitus and Alzheimer's Disease-Like Cognitive Impairment. International Journal of Peptide Research and Therapeutics, 2020, 26, 1243-1249. Polyphenols isolated from lychee seed inhibit Alzheimer's disease-associated Tau through improving 351 2.0 49 insulin resistance via the IRS-1/PI3K/Akt/CSK-3Î<sup>2</sup> pathway. Journal of Ethnopharmacology, 2020, 25Ĩ, 112548. Lack of insulin resistance in response to streptozotocin treatment in neuronal SH-SY5Y cell line. 1.4 Journal of Neural Transmission, 2020, 127, 71-80. An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and 353 Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease. Journal of Alzheimer's 1.2 25 Disease, 2020, 73, 1085-1103. Melatonin attenuates streptozotocin-induced Alzheimer-like features in hyperglycemic rats. 354 Neurochemistry International, 2020, 132, 104601. Markers of adiposity, insulin resistance, prediabetes and cognitive function at baseline of the Brazilian Longitudinal Study of Adult Health (ELSA – Brasil). Diabetes Research and Clinical Practice, 355 1.1 6 2020, 170, 108499. Metabolic Dysregulation Contributes to the Progression of Alzheimer's Disease. Frontiers in 1.4 94 Neuroscience, 2020, 14, 530219. Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to 357 1.1 36 Scientific Assessment. Brain Sciences, 2020, 10, 964. Qingxin Kaiqiao Recipe Improves Cognitive Performance, Inhibits Apoptosis, and Reduces Pathological Deposits in APP/PS1 Double Transgenic Mice via the PI3K/Akt Pathway. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-13. Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α. Cells, 359 30 1.8 2020, 9, 1215. Insulin resistance and Alzheimer's disease. , 2020, , 249-292. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion 361 1.9 94 on Investigational Drugs, 2020, 29, 333-348. Regulation of Adipogenesis and Lipid Deposits by Collapsin Response Mediator Protein 2. International 1.8 Journal of Molecular Sciences, 2020, 21, 2172.

#	Δρτιςι ε	IF	CITATIONS
11	Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in	0.6	120
363	Nonalcoholic Fatty Liver Disease?. Gastroenterology, 2020, 158, 1929-1947.e6.	0.6	120
364	Lean mass index is positively associated with white matter volumes in several brain regions in children with overweight/obesity. Pediatric Obesity, 2020, 15, e12604.	1.4	7
365	Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease. Drug Development Research, 2020, 81, 194-205.	1.4	16
366	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. Medicinal Research Reviews, 2021, 41, 2689-2745.	5.0	26
367	Human gut microbiota Agathobaculum butyriciproducens improves cognitive impairment in LPS-induced and APP/PS1 mouse models of Alzheimer's disease. Nutrition Research, 2021, 86, 96-108.	1.3	38
368	Mitochondrial dysfunction in metabolic disorders. , 2021, , 91-137.		1
369	Dysbiosis and Alzheimer's Disease: Cause or Treatment Opportunity?. Cellular and Molecular Neurobiology, 2022, 42, 377-387.	1.7	24
370	Impact of Genetic Risk Factors for Alzheimer's Disease on Brain Glucose Metabolism. Molecular Neurobiology, 2021, 58, 2608-2619.	1.9	13
371	Pathogenesis of Alzheimer's disease and its treatments: A systematic review. E3S Web of Conferences, 2021, 308, 02012.	0.2	0
372	O-ClcNAcylation and Diabetes. , 2021, , 133-148.		0
373	Suppression of neuronal cholesterol biosynthesis impairs brain functions through insulin-like growth factor I-Akt signaling. International Journal of Biological Sciences, 2021, 17, 3702-3716.	2.6	4
374	Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. Cells, 2021, 10, 1236.	1.8	73
375	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. Journal of Alzheimer's Disease, 2021, 82, 71-105.	1.2	21
376	Association of Dynamic Changes in Metabolic Syndrome Status with the Risk of Parkinson's Disease: A Nationwide Cohort Study. Journal of Parkinson's Disease, 2021, 11, 1-9.	1.5	3
377	Association between thyroid function and Alzheimer's disease: A systematic review. Metabolic Brain Disease, 2021, 36, 1523-1543.	1.4	13
378	Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 8142.	1.8	31
379	Disturbed microbial ecology in Alzheimer's disease: evidence from the gut microbiota and fecal metabolome. BMC Microbiology, 2021, 21, 226.	1.3	38
380	Linsitinib (OSI-906) modulates brain energy metabolism and seizure activity in the lithium-pilocarpine rat model. Acta Epileptologica, 2021, 3, .	0.4	0

#	Article	IF	CITATIONS
381	Analysis of L-leucine amino acid transporter species activity and gene expression by human blood brain barrier hCMEC/D3 model reveal potential LAT1, LAT4, B0AT2 and y+LAT1 functional cooperation. Journal of Cerebral Blood Flow and Metabolism, 2021, , 0271678X2110395.	2.4	1
382	The "Adipo-Cerebral―Dialogue in Childhood Obesity: Focus on Growth and Puberty. Physiopathological and Nutritional Aspects. Nutrients, 2021, 13, 3434.	1.7	8
383	The role of microRNA-34 family in Alzheimer's disease: A potential molecular link between neurodegeneration and metabolic disorders. Pharmacological Research, 2021, 172, 105805.	3.1	23
384	The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radical Biology and Medicine, 2021, 176, 16-33.	1.3	53
385	Cerebrospinal fluid lipidomics for biomarkers of Alzheimer's disease. Molecular Omics, 2021, 17, 454-463.	1.4	21
387	Genomic Imprinting and Human Psychology: Cognition, Behavior and Pathology. Advances in Experimental Medicine and Biology, 2008, 626, 71-88.	0.8	22
388	Lipid Mediators in Metabolic Syndrome and Neurological Disorders. , 2013, , 103-141.		1
389	Metabolic Syndrome as a Risk Factor for Alzheimer Disease. , 2013, , 281-341.		3
390	Pathobiology of Diabetic Encephalopathy in Animal Models. , 2009, , 409-431.		2
391	Alcohol-Related Liver Disease: Roles of Insulin Resistance, Lipotoxic Ceramide Accumulation, and Endoplasmic Reticulum Stress. , 2013, , 507-522.		4
392	Release of insulin produced by the choroid plexis is regulated by serotonergic signaling. JCI Insight, 2019, 4, .	2.3	60
393	Cognitive dysfunctions in individuals with diabetes mellitus. Yeungnam University Journal of Medicine, 2019, 36, 183-191.	0.7	42
394	The neuronal functions of human apolipoprotein E. OA Biochemistry, 2013, 1, .	0.1	2
395	Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer's Disease. Journal of Parkinson's Disease and Alzheimer's Disease, 2018, 5, 01-08.	1.5	12
396	Animal models of Alzheimer disease: historical pitfalls and a path forward. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 279-302.	0.9	95
397	Cervical Vagal Schwannoma Review of all Reported Cases and Our Reports. International Journal of Neurology and Brain Disorders, 2016, 3, 1-6.	0.0	5
398	INSULIN AND INSULIN RESISTANCE: NEW MOLECULE MARKERS AND TARGET MOLECULE FOR THE DIAGNOSIS AND THERAPY OF DISEASES OF THE CENTRAL NERVOUS SYSTEM. Bulletin of Siberian Medicine, 2013, 12, 104-118.	0.1	6
399	Neuroprotective Effect of Garcinia Mangostana on Streptozotocin Induced Sporadic Type Alzheimer's Disease in Mice. International Journal of Applied Pharmaceutical Sciences and Research, 2016, 1, 8-15.	0.2	3

#	Article	IF	CITATIONS
400	The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1345-1355.	0.9	3
401	Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin. Current Alzheimer Research, 2015, 12, 785-795.	0.7	31
402	Insulin Resistance in Brain and Possible Therapeutic Approaches. Current Vascular Pharmacology, 2014, 12, 553-564.	0.8	36
403	Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2014, 13, 305-311.	0.8	94
404	Diabetes of the Brain: Computational Approaches and Interventional Strategies. CNS and Neurological Disorders - Drug Targets, 2014, 13, 408-417.	0.8	16
405	Extending Arms of Insulin Resistance from Diabetes to Alzheimer's Disease: Identification of Potential Therapeutic Targets. CNS and Neurological Disorders - Drug Targets, 2019, 18, 172-184.	0.8	14
406	Cardiovascular Dementia - A Different Perspective. The Open Biochemistry Journal, 2010, 4, 29-52.	0.3	21
407	The Association between Adiponectin, Insulin and Troponin I in Patients with Acute Myocardial Infarction. Journal of Al-Nahrain University-Science, 2012, 15, 15-22.	0.1	1
408	Therapeutic targets of brain insulin resistance in sporadic Alzheimer s disease. Frontiers in Bioscience - Elite, 2012, E4, 1582-1605.	0.9	50
409	Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer's Disease: Co-Factor Role of Apolipoprotein E ɛ4. Journal of Alzheimer's Disease Reports, 2020, 4, 479-493.	1.2	7
410	Sweet but Bitter: Focus on Fructose Impact on Brain Function in Rodent Models. Nutrients, 2021, 13, 1.	1.7	155
411	Effects of Chinese herbal medicine Yinsiwei compound on spatial learning and memory ability and the ultrastructure of hippocampal neurons in a rat model of sporadic Alzheimer disease. Zhong Xi Yi Jie He Xue Bao, 2011, 9, 209-215.	0.7	8
412	Eleutheroside B or E enhances learning and memory in experimentally aged rats. Neural Regeneration Research, 2013, 8, 1103-12.	1.6	14
413	Prediabetes and alzheimer's disease. Indian Journal of Pharmaceutical Sciences, 2015, 77, 511.	1.0	13
414	Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. Neural Regeneration Research, 2018, 13, 1995.	1.6	18
415	Motor Function Deficits Following Chronic Prenatal Ethanol Exposure are Linked to Impairments in Insulin/ICF, Notch and Wnt Signaling in the Cerebellum. Journal of Diabetes & Metabolism, 2012, 04, .	0.2	10
416	Insulin Resistance: A Bridge between T2DM and Alzheimer's Disease. Journal of Diabetes & Metabolism, 2013, 04, .	0.2	1
417	Sustained Impairments in Brain Insulin/Igf Signaling in Adolescent Rats Subjected to Binge Alcohol Exposure during Development. , 2012, 02, .		19

	CITATION	Report	
#	Article	IF	CITATIONS
418	Insulin resistance and Alzheimer's disease. BMB Reports, 2009, 42, 475-481.	1.1	338
419	Effects of treadmill exercise on brain insulin signaling and β-amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats. Journal of Exercise Nutrition & Biochemistry, 2014, 18, 89-96.	1.3	28
420	Insulin Resistance, Cognitive Impairment and Neurodegeneration: Roles of Nitrosamine Exposure, Diet and Lifestyles. , 0, , .		3
421	Mechanism of action of yoga on prevention and management of type 2 diabetes mellitus: Narrative review. Journal of Bodywork and Movement Therapies, 2022, 29, 134-139.	0.5	7
422	The Role of Insulin Resistance in Age-Related Cognitive Decline and Dementia. , 2009, , 433-457.		0
423	Neuroimaging of Cardiovascular Disease. , 2011, , 215-255.		1
424	Perspective and Direction for Future Research. , 2013, , 379-398.		0
426	Cerebral ageing-the role of insulin and insulin-like growth factor signalling: A review. World Journal of Neurology, 2014, 4, 12.	0.6	0
427	Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes. CNS and Neurological Disorders - Drug Targets, 2014, 13, 203-212.	0.8	1
428	Effects of Treadmill Exercise on Brain Insulin Signaling, Glucose Metabolism and Tau Hyperphosphorylation in Intracerebroventricular Streptozotocin Induced-Memory Impairment in Rats. Exercise Science, 2014, 23, 99-108.	0.1	0
429	Aging: Thromboembolic Disease, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Alzheimer's Disease. Journal of Biosciences and Medicines, 2016, 04, 1-20.	0.1	1
430	Development of regional specificity of spinal and medullary dorsal horn neurons. World Journal of Biological Chemistry, 2016, 7, 138.	1.7	0
431	Potential Co-Factor Role of Tobacco Specific Nitrosamine Exposures in the Pathogenesis of Fetal Alcohol Spectrum Disorder. Gynecology and Obstetrics Research: Open Journal, 2016, 2, 112-125.	1.6	2
432	Cases of amyloidosis with diabetic encephalopathy. Vestnik of Russian Military Medical Academy, 2018, 20, 58-62.	0.1	0
433	Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer's Disease. , 0, , 123-145.		0
435	Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. Journal of Alzheimer's Disease, 2009, 17, 827-44.	1.2	92
436	Role of central nervous system insulin resistance in fetal alcohol spectrum disorders. Journal of Population Therapeutics and Clinical Pharmacology, 2010, 17, e390-404.	1.4	22
437	Effects of intravitreal insulin and insulin signaling cascade inhibitors on emmetropization in the chick. Molecular Vision, 2012, 18, 2608-22.	1.1	14

~		<b>_</b>	
(1T)	ΔΤΙΟΝΙ		Т
		ICLI ON	

#	Article	IF	CITATIONS
439	Motor Function Deficits Following Chronic Prenatal Ethanol Exposure are Linked to Impairments in Insulin/IGF, Notch and Wnt Signaling in the Cerebellum. Journal of Diabetes & Metabolism, 2013, 4, 238.	0.2	11
440	Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Medica, 2012, 54, 171-8.	0.2	32
442	Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Current Opinion in Investigational Drugs, 2009, 10, 1049-60.	2.3	99
445	Differential Effects of 3rd Trimester-Equivalent Binge Ethanol and Tobacco-Specific Nitrosamine Ketone Exposures on Brain Insulin Signaling in Adolescence. , 2016, 1, .		3
446	Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia. CNS and Neurological Disorders - Drug Targets, 2022, 21, 542-556.	0.8	5
447	A Non-Invasive Determination of Ketosis-Induced Elimination of Chronic Daytime Somnolence in a Patient with Late-Stage Dementia (Assessed with Type 3 Diabetes): A Potential Role of Neurogenesis. Journal of Alzheimer's Disease Reports, 2021, 5, 1-20.	1.2	0
448	Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial. Scientific Reports, 2022, 12, 1346.	1.6	22
449	The interactions between adipose tissue secretions and Parkinson's disease: The role of leptin. European Journal of Neuroscience, 2022, 55, 873-891.	1.2	3
450	Type 3 diabetes (T3D) and alzheimer's disease (AD). Current Trends in Pharmacy and Pharmaceutical Chemistry, 2022, 4, 8-12.	0.1	0
451	A Bioinformatics Approach Toward Unravelling the Synaptic Molecular Crosstalk Between Alzheimer's Disease and Diabetes. Journal of Alzheimer's Disease, 2022, , 1-17.	1.2	3
452	Alteration in glucose metabolism in the brain associated with tamoxifen treatment: Study in postmenopausal animal model. Toxicology and Applied Pharmacology, 2022, 442, 116002.	1.3	2
453	Intranasal metformin treatment ameliorates cognitive functions via insulin signaling pathway in ICV-STZ-induced mice model of Alzheimer's disease. Life Sciences, 2022, 299, 120538.	2.0	14
455	Is the Brain Undernourished in Alzheimer's Disease?. Nutrients, 2022, 14, 1872.	1.7	7
456	Mechanistic insight into inhibition of amyloid fibrillation of human serum albumin by Vildagliptin. Colloids and Surfaces B: Biointerfaces, 2022, 216, 112563.	2.5	3
457	Effect of Letrozole on hippocampal Let-7 microRNAs and their correlation with working memory and phosphorylated Tau protein in an Alzheimer's disease-like rat model. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	0.4	1
458	A Brief Atlas of Insulin. Current Diabetes Reviews, 2022, 19, .	0.6	2
459	Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs. Frontiers in Aging, 0, 3, .	1.2	3
460	Alteration of Gut Microbiota in Alzheimer's Disease and Their Relation to the Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 88, 1103-1114.	1.2	18

#	Article	IF	CITATIONS
461	Associations of Circulating Insulin-Growth Factor-1 With Cognitive Functions and Quality of Life Domains in Ambulatory Young Adults With Cerebral Palsy: A Pilot Study. Frontiers in Neurology, 0, 13,	1.1	0
462	MiR-702-5p ameliorates diabetic encephalopathy in db/db mice by regulating 12/15-LOX. Experimental Neurology, 2022, 358, 114212.	2.0	5
463	The Gut Microbiota Dysbiosis as a Trigger of Inflammation-Driving Pathogensis of Alzheimer's Disease. , 0, 8, 306-313.		0
464	Prediction value of the genetic risk of type 2 diabetes on the amnestic mild cognitive impairment conversion to Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
465	Role of Impaired Insulin Signaling in the Pathogenesis of Dementia. , 2022, , 63-84.		0
466	Dietary Soy Prevents Fetal Demise, Intrauterine Growth Restriction, Craniofacial Dysmorphic Features, and Impairments in Placentation Linked to Gestational Alcohol Exposure Pivotal Role of Insulin and Insulin-Like Growth Factor Signaling Networks. SSRN Electronic Journal, 0, , .	0.4	0
467	Clinical and metabolic features of diabetic encephalopathy. HERALD of North-Western State Medical University Named After I I Mechnikov, 2022, 14, 93-100.	0.1	0
468	Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis. Neuroscience, 2022, 505, 91-110.	1.1	2
469	A Pathophysiological Intersection of Diabetes and Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 11562.	1.8	6
470	Overview of Neuroglia Activation, Chronic Neuroinflammation, Remodeling, and Impaired Cognition Due to Perivascular Adipose Tissue-Derived Extracellular Vesicle Exosomes in Obesity and Diabetes. Neuroglia (Basel, Switzerland), 2022, 3, 112-138.	0.3	3
471	Plant bioactives in balancing glucose homeostasis during aging and related diseases. , 2023, , 63-83.		0
472	Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, .	4.4	9
473	Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 15287.	1.8	26
474	Miracle fruit seed as a potential supplement for the treatment of learning and memory disorders in Alzheimer's disease. Frontiers in Pharmacology, 0, 13, .	1.6	1
475	Ferulic acid alleviates high fat diet-induced cognitive impairment by inhibiting oxidative stress and apoptosis. European Journal of Pharmacology, 2023, 946, 175642.	1.7	5
476	What the Gut Tells the Brain—Is There a Link between Microbiota and Huntington's Disease?. International Journal of Molecular Sciences, 2023, 24, 4477.	1.8	4
477	The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 4643.	1.8	7
478	Dietary Soy Prevents Fetal Demise, Intrauterine Growth Restriction, Craniofacial Dysmorphic Features, and Impairments in Placentation Linked to Gestational Alcohol Exposure: Pivotal Role of Insulin and Insulin-Like Growth Factor Signaling Networks. Alcohol, 2023, , .	0.8	2

	Ci	CITATION REPORT		
#	Article	IF	CITATIONS	
479	Investigation of Cyclo-Z Therapeutic Effect on Insulin Pathway in Alzheimer's Rat Model: Biochemical and Electrophysiological Parameters. Molecular Neurobiology, 2023, 60, 4030-4048.	1.9	1	
480	Differential Early Mechanistic Frontal Lobe Responses to Choline Chloride and Soy Isoflavones in an Experimental Model of Fetal Alcohol Spectrum Disorder. International Journal of Molecular Sciences, 2023, 24, 7595.	1.8	0	
486	Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management. Nature Reviews Neurology, 2023, 19, 668-687.	4.9	3	